Patent · US Active

Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib

US11819487B2 · kind B2 · utility

6Cited by

3References

21Claims

0Family size

Assignee

SpringWorks Therapeutics, Inc. · US

Inventors

Uchenna H. Iloeje · Stamford, US
Abraham J. Langseth · Stamford, US
Todd Webster Shearer · Stamford, US

Key dates

Filing date	Mar 16, 2023
Grant date	Nov 21, 2023
Priority date	—
Expiry date	Mar 16, 2043

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.